Keyphrases
Endometrial Cancer
77%
Ovarian Cancer
53%
Gynecologic Oncology
40%
Overall Survival
35%
Recurrent Endometrial Cancer
28%
Tumor
28%
Oncology Patients
26%
Chemotherapy
26%
Gynecologic Oncology Group
26%
Cancer Patients
21%
Group Studies
20%
Dostarlimab
20%
Obesity
19%
Paclitaxel
18%
Confidence Interval
17%
Radiation Therapy
16%
Receptor Tyrosine Kinase
15%
Gynecologic Cancer Survivors
15%
ENGOT
15%
Progression-free Survival
15%
Metastasis
15%
Uterine Serous Carcinoma
14%
Microsatellite Instability-high (MSI-H)
13%
Ovarian Cancer Cells
13%
AXL Inhibition
12%
Fallopian Tube
12%
Weight Loss
12%
Cervical Cancer
11%
Taxanes
11%
National Cancer Institute
11%
Randomized Controlled Trial
10%
Poor Prognosis
10%
Capivasertib
10%
E17K
10%
Behavioral Weight Loss
10%
Text Messaging
10%
AKT1
10%
Message-based
10%
Gynecologic Malignancies
10%
Non-randomized Trial
10%
Salophenes
10%
Iron(III)
10%
NRG Oncology
10%
Phase I Trial
10%
COVID-19 Pandemic Impact
10%
OR-PAM
10%
Extracellular Matrix Protein 1 (ECM1)
10%
High-grade Serous Ovarian Cancer (HGSOC)
10%
Tumor Burden
10%
Ovarian Cancer Patients
9%
Medicine and Dentistry
Uterine Cancer
100%
Ovarian Cancer
67%
Neoplasm
57%
Gynecological Oncology
56%
Malignant Neoplasm
44%
Overall Survival
31%
Metastatic Carcinoma
27%
Cancer
24%
Diseases
22%
Progression Free Survival
21%
Paclitaxel
19%
Randomized Controlled Trial
16%
Radiation Therapy
15%
Cell Line
14%
Protein Tyrosine Kinase
13%
Female Genital Tract Cancer
13%
Fallopian Tube
13%
Pelvis
13%
Arm
12%
Body Mass Index
12%
Cervical Cancer
12%
Cancer Cell
11%
Magnetic Resonance Imaging
11%
Squamous Cell Carcinoma
10%
Clinical Trial
10%
Photoacoustic Microscopy
10%
COVID-19
10%
Phase II Trials
10%
Recurrent Ovarian Cancer
10%
Vulva
10%
Cancer Surgery
10%
Oncology
10%
In Vitro
9%
Lymph Node Metastasis
9%
Recurrent Disease
9%
Patient Referral
8%
Quality of Life
8%
Wound Complication
8%
Biological Marker
8%
Surgery
7%
Comorbidity
7%
Paraaortic Lymph Node
7%
Poly ADP Ribose Polymerase
7%
Biopsy Technique
7%
Primary Health Care
6%
Tumor Cell
6%
Programmed Cell Death
6%
Protein Expression
6%
Logistic Regression Analysis
5%
Cancer Therapy
5%